Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Schiff

Showing results (71-80 of 199) with videos related to

Pageof 20
Sort By:
Breast (Edinburgh, Scotland)|October 21, 2005
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne, Rachel Schiff, Grazia Arpino, et al.
Molecular Cancer Research : MCR|August 5, 2016
Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M CheckpointJin-Ah Kim, Meenakshi Anurag, Jamunarani Veeraraghavan, et al.
Molecular and Cellular Biology|December 30, 2010
Compartmentalized Ras proteins transform NIH 3T3 cells with different efficienciesChiang-Min Cheng, Huiling Li, Stéphane Gasman, et al.
Molecular Endocrinology (Baltimore, Md.)|May 6, 2003
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison, Rafael E Herrera, Ester Coronado Heinsohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Metastasis dormancy in estrogen receptor-positive breast cancerXiang H-F Zhang, Mario Giuliano, Meghana V Trivedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Plos One|November 19, 2013
Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 productionYi Zhang, Chun-Chih Tseng, Yuan-Li Tsai, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Journal of the National Cancer Institute|June 17, 2004
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou, Suleiman Massarweh, C Kent Osborne, et al.
Pharmacotherapy|June 8, 2013
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancerJennifer Parma, Anne Pavlick, Rachel Schiff, et al.
Pageof 20

Showing results (71-80 of 199) with videos related to

Sort By:
Pageof 20
Breast (Edinburgh, Scotland)|October 21, 2005
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapyC Kent Osborne, Rachel Schiff, Grazia Arpino, et al.
Molecular Cancer Research : MCR|August 5, 2016
Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M CheckpointJin-Ah Kim, Meenakshi Anurag, Jamunarani Veeraraghavan, et al.
Molecular and Cellular Biology|December 30, 2010
Compartmentalized Ras proteins transform NIH 3T3 cells with different efficienciesChiang-Min Cheng, Huiling Li, Stéphane Gasman, et al.
Molecular Endocrinology (Baltimore, Md.)|May 6, 2003
Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptorAshby J Morrison, Rafael E Herrera, Ester Coronado Heinsohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Metastasis dormancy in estrogen receptor-positive breast cancerXiang H-F Zhang, Mario Giuliano, Meghana V Trivedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Plos One|November 19, 2013
Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 productionYi Zhang, Chun-Chih Tseng, Yuan-Li Tsai, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Journal of the National Cancer Institute|June 17, 2004
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou, Suleiman Massarweh, C Kent Osborne, et al.
Pharmacotherapy|June 8, 2013
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancerJennifer Parma, Anne Pavlick, Rachel Schiff, et al.
Pageof 20